Injectable physiologically adaptive intraocular lenses (IOL's)

    公开(公告)号:US10278810B2

    公开(公告)日:2019-05-07

    申请号:US13096729

    申请日:2011-04-28

    Abstract: A device and method for forming an adaptive optic in the capsule of a human eye is disclosed, comprising a capsular interface enclosing an optically acceptable medium. The device establishes a physiologic range of optical power in response to a range of ciliary contractile states. The preferred bi-phasic medium of the device is comprised of a solid three dimensional polymeric network suspended in a liquid aqueous phase and bonded to a capsular interface. The polymeric network provides shape to the capsular interface, optical power, and a physiologic response to the suspensory ligament. The three dimensional network of the bi-phasic medium mimics the stacked fiber configuration and elasticity of a natural lens. An alternative embodiment utilizing a single phase medium is also disclosed with associated structural features provided in the capsular interface.

    Disc annulus closure
    2.
    发明授权
    Disc annulus closure 有权
    盘环封闭

    公开(公告)号:US08869802B2

    公开(公告)日:2014-10-28

    申请号:US13086754

    申请日:2011-04-14

    Abstract: Disclosed herein are methods for treating a defect in a spinal disc nuclear space, comprising: (a) creating an opening by open, percutaneous or laparoscopic techniques to access the defect in the nuclear space; (b) removing a desired amount of tissue from the nuclear space; (c) positioning a delivery catheter through the opening; (d) fluidically isolating the nuclear space by blocking the opening with a blocking component of the catheter; (e) delivering an in-situ curable liquid material through a lumen of the catheter to the nuclear space; and (f) maintaining the isolating until the liquid material has cured. Also disclosed are treatment systems and materials for prostheses.

    Abstract translation: 本文公开了用于治疗脊椎椎间盘核空间缺陷的方法,其包括:(a)通过开放,经皮或腹腔镜技术产生开放以接近核空间中的缺陷; (b)从核空间中去除所需量的组织; (c)将输送导管定位通过所述开口; (d)通过用导管的阻挡部件阻塞开口来流体地隔离核空间; (e)将原位可固化的液体材料通过导管的内腔递送到核空间; 和(f)保持隔离直到液体材料固化。 还公开了用于假体的处理系统和材料。

    In situ bulking composition
    3.
    发明授权
    In situ bulking composition 有权
    原位填充组合物

    公开(公告)号:US08604099B2

    公开(公告)日:2013-12-10

    申请号:US13422448

    申请日:2012-03-16

    CPC classification number: A61L27/50 A61F2/0036 A61L27/18 C08L75/04

    Abstract: The present invention relates to a hydrated, biocompatible tissue-augmentation compound and methodology for its implantation into mammalian tissue. The tissue-augmentation compound is comprised of: living tissue, optionally body derived fluids, and at least one NCO-terminated hydrophilic urethane prepolymer derived from an organic polyisocyanate, and oxyethylene-containing diols or polyols in which essentially all of hydroxyl groups are capped with polyisocyanate.

    Abstract translation: 本发明涉及水合的生物相容性组织增加化合物及其植入哺乳动物组织的方法。 组织增强化合物包括:活组织,任选的身体衍生的流体,以及至少一种衍生自有机多异氰酸酯的至少一种NCO封端的亲水氨基甲酸酯预聚物和含氧乙烯的二醇或多元醇,其中基本上所有的羟基被封端 多异氰酸酯。

    Passive cardiac restraint systems having multiple layers of inflatable elements
    4.
    发明授权
    Passive cardiac restraint systems having multiple layers of inflatable elements 有权
    被动心脏约束系统具有多层可充气元件

    公开(公告)号:US06547716B1

    公开(公告)日:2003-04-15

    申请号:US09723565

    申请日:2000-11-28

    Abstract: A non-blood contacting, implantable heart assist system surrounds the natural heart and provides resistance to cardiac hypertrophy. The restraint system is composed of adjacent tube pairs arranged along a bias with respect to the axis of the heart and bound in a non-distensible sheath forming a heart wrap. The tube pairs are tapered at both ends such that when they are compressed they approximately follow the surface of the myocardium. Inflation of the tube pairs with a compressible fluid causes the wrap to exert a restraining force on the heart to prevent overexpansion during diastole.

    Abstract translation: 非血液接触植入式心脏辅助系统围绕天然心脏并提供对心脏肥大的抵抗力。 约束系统由相对于心脏的轴线的偏置布置的相邻管对组成并且结合在形成心脏包裹物的不可扩张的鞘中。 管对在两端是锥形的,使得当它们被压缩时,它们大致跟随心肌的表面。 管对与可压缩流体的膨胀导致包裹对心脏施加约束力以防止舒张期期间的过度扩张。

    Eye fundus tracker/stabilizer
    5.
    发明授权
    Eye fundus tracker/stabilizer 失效
    眼底视力/稳定器

    公开(公告)号:US4856891A

    公开(公告)日:1989-08-15

    申请号:US14994

    申请日:1987-02-17

    Abstract: An eye movement tracker for stabilizing in two dimensions a diagnostic, treatment or other ophthalmic illumination on the fundus has a laser source which produces a narrow directed tracking beam, an optical steering assembly for controllably directing the beam to illuminate a region of the fundus, and an optical imaging assembly for imaging the illuminated region on a spatially-distributed photodetecting element. A tracking circuit scans the detecting element to detect motion of a spatially variant intensity feature and controls the optical steering assembly to redirect the optical path and maintain the feature in a fixed position. This repositions the diagnostic or other illumination, maintaining it in a fixed position on the fundus during eye movement. Scanning rates many times those of conventional systems are achieved, effectively stabilizing even very rapid eye movements. A viewing port provides an operator with a 30 degree field of the subject's eye fundus.

    IN SITU BULKING COMPOSITION
    6.
    发明申请
    IN SITU BULKING COMPOSITION 有权
    在现场组装

    公开(公告)号:US20130035415A1

    公开(公告)日:2013-02-07

    申请号:US13422448

    申请日:2012-03-16

    CPC classification number: A61L27/50 A61F2/0036 A61L27/18 C08L75/04

    Abstract: The present invention relates to a hydrated, biocompatible tissue-augmentation compound and methodology for its implantation into mammalian tissue. The tissue-augmentation compound is comprised of: living tissue, optionally body derived fluids, and at least one NCO-terminated hydrophilic urethane prepolymer derived from an organic polyisocyanate, and oxyethylene-containing diols or polyols in which essentially all of hydroxyl groups are capped with polyisocyanate.

    Abstract translation: 本发明涉及水合的生物相容性组织增加化合物及其植入哺乳动物组织的方法。 组织增强化合物包括:活组织,任选的身体衍生的流体,以及至少一种衍生自有机多异氰酸酯的至少一种NCO封端的亲水氨基甲酸酯预聚物和含氧乙烯的二醇或多元醇,其中基本上所有的羟基被封端 多异氰酸酯。

    Anti-Adhesion Alginate Barrier of Variable Absorbance
    7.
    发明申请
    Anti-Adhesion Alginate Barrier of Variable Absorbance 审中-公开
    抗粘附海藻酸盐屏障的可变吸光度

    公开(公告)号:US20120039959A1

    公开(公告)日:2012-02-16

    申请号:US13211226

    申请日:2011-08-16

    CPC classification number: A61L27/20 A61L27/54 A61L31/042 A61L31/16 C08L5/04

    Abstract: Described are mono- and bi-layer alginate post-surgical anti-adhesion barriers with tailored absorption profiles and non-migrating characteristics. Muco-adhesive properties of alginates in their solid state are used to localize the device, and lubricious properties of alginates in their liquid state are used to mitigate adhesion formation during wound healing. In addition, the design of the implant can be selected such that the crosslinking agent is released from the device under specific conditions and the absorbance profile modified. A medicinal agent may optionally be incorporated.

    Abstract translation: 描述了具有定制的吸收曲线和非迁移特性的单层和双层藻酸盐后手术抗粘连屏障。 使用固态藻酸盐的粘稠粘合性能来定位装置,并且使用其液态藻酸盐的润滑性能来减轻伤口愈合期间的粘附形成。 此外,可以选择植入物的设计,使得交联剂在特定条件下从装置释放并且修改吸光度分布。 可以任选地并入药剂。

    Reversibly gelling polyurethane composition for surgical repair and augmentation
    8.
    发明授权
    Reversibly gelling polyurethane composition for surgical repair and augmentation 有权
    反射胶凝聚氨酯组合物进行手术修复和增强

    公开(公告)号:US08114157B2

    公开(公告)日:2012-02-14

    申请号:US12162039

    申请日:2007-01-24

    Abstract: A new reversibly gelling polyurethane (RGP) polymer composition is described, as well as novel processes for its preparation, and its medical uses for filling spaces in tissue, or bulking tissue, or for restoring organ function. The novel RGP polymer forms a gel on standing, liquefies during shear and reversibly reforms a macroscopic gel on standing after being sheared. Methods of use include delivering the improved gel to a site on the body to fill voids or to augment local tissue bulk.

    Abstract translation: 描述了新的可逆胶凝聚氨酯(RGP)聚合物组合物,以及其制备的新方法及其用于填充组织或膨胀组织中的空间或恢复器官功能的医疗用途。 新型RGP聚合物在静置时形成凝胶,在剪切过程中液化并在剪切后可立即重新形成宏观凝胶。 使用的方法包括将改进的凝胶递送到身体上的部位以填充空隙或增加局部组织体积。

    IN SITU BULKING COMPOSITION
    9.
    发明申请
    IN SITU BULKING COMPOSITION 审中-公开
    在现场组装

    公开(公告)号:US20110135700A1

    公开(公告)日:2011-06-09

    申请号:US13017129

    申请日:2011-01-31

    CPC classification number: A61L27/50 A61F2/0036 A61L27/18 C08L75/04

    Abstract: The present invention relates to a hydrated, biocompatible tissue-augmentation compound and methodology for its implantation into mammalian tissue. The tissue-augmentation compound is comprised of: living tissue, optionally body derived fluids, and at least one NCO-terminated hydrophilic urethane prepolymer derived from an organic polyisocyanate, and oxyethylene-containing diols or polyols in which essentially all of hydroxyl groups are capped with polyisocyanate.

    Abstract translation: 本发明涉及水合的生物相容性组织增加化合物及其植入哺乳动物组织的方法。 组织增强化合物包括:活组织,任选的身体衍生的流体,以及至少一种衍生自有机多异氰酸酯的至少一种NCO封端的亲水氨基甲酸酯预聚物和含氧乙烯的二醇或多元醇,其中基本上所有的羟基被封端 多异氰酸酯。

Patent Agency Ranking